The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
Showing 25 of 1781
The company’s managing director continues to welcome new investment subscriptions.
The updated average reduction in pain score is 51.2% compared to 15% for opioids.
The company's patent portfolio comprises 60 patents and applications in 13 patent families.
Cellmid is now focused on implementing a cost-effective experiential marketing solution.
Legalisation for the recreational use of cannabis in Canada on October 17, 2018, will result in the accelerated growth of this nascent industry.
The partnership with the US-based network will give Paradigm substantial exposure and access to a large patient pool.
The company is focused on repurposing PPS, an FDA approved drug.
Last month, Edison increased their valuation for Regeneus to 87 cents per share.
There were no adverse safety findings and excellent drug-like properties were confirmed.
New skincare formulations are to be developed with Affinity’s algae and cannabis oils.
The company’s shares are trading about 121% higher intra-day, at 4.2 cents.
Patients can access the company's drug through the TGA special access scheme.
Discovered a compound that is a potent inhibitor of IRAK4 protein which causes chronic inflammation including autoimmune diseases.
KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody.
The company's revenue increased $120.0 million to $879.0million in FY2018.
Ed Rayner is an investment director for major shareholder Arix Bioscience Plc (LSE:ARIX).
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
The milk will be promoted on China’s JiaJia TV shopping channel which has 385 million viewers.
The company sells clinically validated anti-ageing products for hair, skin and body.
The company recommenced trading today up 13.3% to 3.4 cents per share.
Cellmid can now apply to the US FDA and European EMA for Orphan Drug Designation for CAB102.
The company has bounced off its July low of 88 cents to be trading at 99 cents today.
Funds raised in the IPO will be used to acquire more podiatry and physio businesses.
The company’s chief executive Nicholas Simms will speak at the first ASX Small and Mid-Cap Conference in Sydney on Thursday.